## Diagnosis: Chronic Rhinosinusitis with Nasal Polyposis ### Clinical Presentation The patient presents with: - Bilateral, pale, smooth, glistening polyps (classic appearance) - Progressive nasal obstruction over 2 years - Recurrent rhinosinusitis - Bilateral sinus involvement on imaging - Absence of asthma or aspirin sensitivity (atypical for allergic polyps, but not exclusionary) ### Key Diagnostic Features **Key Point:** Chronic rhinosinusitis with nasal polyposis (CRSwNP) is characterized by bilateral polypoidal masses arising from the ethmoid sinuses, with pale, smooth, translucent appearance on endoscopy. **High-Yield:** The hallmark is **bilateral involvement** — this distinguishes CRSwNP from unilateral lesions like antrochoanal polyp or inverted papilloma. ### Pathophysiology CRSwNP results from chronic inflammation with: - Eosinophilic infiltration (Type 2 inflammation) - Increased mucin production - Tissue edema and remodeling - Polyp formation from ethmoid mucosa ### Differential Considerations | Feature | CRSwNP | Antrochoanal Polyp | Allergic Fungal Sinusitis | Inverted Papilloma | |---------|--------|-------------------|---------------------------|--------------------| | **Laterality** | Bilateral | Unilateral | Usually unilateral | Unilateral | | **Origin** | Ethmoid sinus | Maxillary sinus | Paranasal sinuses | Lateral nasal wall | | **Appearance** | Pale, smooth, glistening | Single stalk, smooth | Opacified sinuses, allergic mucin | Granular, cerebriform | | **Age** | Middle-aged adults | Children/young adults | Atopic individuals | Older adults | | **Malignant potential** | No | No | No | Yes (10–15%) | **Clinical Pearl:** CRSwNP is associated with Type 2 inflammation (elevated eosinophils, IL-5, IL-13) and may coexist with asthma and NSAID sensitivity (Samter's triad), though absence of these does not exclude the diagnosis. ### Management Approach 1. **Medical:** Intranasal corticosteroids (first-line) 2. **Surgical:** Functional endoscopic sinus surgery (FESS) for symptomatic polyps unresponsive to medical therapy 3. **Biologic therapy:** Dupilumab (anti-IL-4Rα) for severe, recurrent CRSwNP **Tip:** Always assess for associated asthma and atopy; CRSwNP is a marker of Type 2 inflammation. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.